Adult patients with high-grade B-cell lymphoma undergoing treatment with CD19 chimeric antigen receptor (CAR) T-cells. research hub

Investigating infection risk and the microbiome in blood cancer patients treated with CD19 CAR-T therapy

This study looks at infections in blood cancer patients treated with a new therapy called CAR-T. It aims to understand why infections happen, who is most at risk, and how tiny germs (microbes) in the body affect recovery and infection chances after this treatment.